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1114 The Journal of Thoracic and CardObjective: It has been reported that unmatched adult bone marrow stromal cells
could be tolerated by immune-competent allotransplant or xenotransplant recipients
under various conditions. This study examined whether xenogeneic bone marrow
stromal cells implanted immediately after myocardial infarction can survive and
differentiate, attenuating deterioration in left ventricular function.
Methods: In groups I and II (n  34), myocardial infarctions were created in
immunocompetent adult Lewis rats by proximal left coronary artery ligation. In
group I, 3  106 lacZ-labeled mouse bone marrow stromal cells were immediately
injected into the peri-infarct area of the left ventricle, whereas in group II, only
culture medium was injected. There were 10 early and 4 late deaths. At 4 weeks
after injection, hearts were stained for -galactosidase and troponin IC. In groups
IIIA and IIIB, lacZ-labeled mouse skin fibroblasts were implanted into rat myocar-
dium (n  10 each) with and without left coronary artery ligation, respectively, and
the rats were killed serially. In group IV, animals underwent sham surgery (n  5,
no deaths). At 4 weeks, surviving rats in groups I, II, and IV (n  10, n  10, and
n  5, respectively) underwent blinded transthoracic echocardiography for ventric-
ular function studies.
Results: In group I, labeled mouse-derived bone marrow stromal cells were found
within rat myocardium that stained positively for troponin IC 4 weeks after implan-
tation. Functionally, mean left ventricular ejection fraction (P  .007), stroke
volume (P  .03), and fractional shortening (P  .02) were all significantly higher
in group I than in group II. In groups IIIA and IIIB, mouse fibroblasts induced
cellular infiltration with rapid loss of donor cells. No labeled cells were found after
4 days. In group IV, there was no change in cardiac function.
Conclusion: Xenogeneic bone marrow stromal cells implanted into acutely ischemic
myocardium induced by coronary artery ligation were immunologically tolerated,
survived and differentiated, resulting in a cardiac chimera which improved left
ventricular function. This unique immunologic tolerance may suggest the feasibility
of using bone marrow stromal cells as universal donor cells.
Bone marrow stromal cells (MSCs) contain multipotent adult stem cellscapable of differentiation into both mesenchymal and nonmesenchymallineages.1-6 When injected directly into the myocardium, subpopulations
of MSCs have been shown to incorporate themselves into the host myocardium
and differentiate into cardiomyocytes.7 There is a growing body of evidence that
MSCs possess unique immune modulatory capabilities.8 Liechty and colleagues9
have demonstrated that human MSCs could engraft in fetal sheep after intra-
peritoneal implantation, even after the development of immune competence.
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months in host tissues without the use of immunosup-
pression. Recently, our group has reported that xenoge-
neic MSCs injected intravenously into adult rodents
could be recruited and engraft damaged myocardium and
survive in the absence of immunosuppression, forming a
cardiac chimera.10 However, whether such transplanted
xenogenic MSCs might survive in the microenvironment
of acute myocardial infarction to differentiate and affect
left ventricular (LV) performance has not been investi-
gated. In this study, we sought answers to these questions
and further documented the unique nature of MSC im-
mune tolerance by comparing the responses between
MSCs and differentiated fibroblasts when both were used
as xenogeneic donor cells.
Material and Methods
Animals
Female C57Bl/6 mice and male Lewis rats were used in this
study as the donors and recipients, respectively. All animals
received humane care in compliance with the “Guide for the
Care and Use of Laboratory Animals” (http://www.nap.edu/
catalog/5140.html) and the “Guide to the Care and Use of
Experimental Animals” of the Canadian Council on Animal
Care.
Experimental Design
A total of 34 rats underwent open-chest coronary artery liga-
tions, and the animals were randomly assigned at the time of
operation. In group I, labeled mouse MSCs (3  106) were
injected directly into the peri-ischemic region of rat myocar-
dium 15 minutes after ligation of the proximal left coronary
artery. In group II, a similar volume of culture medium was
injected into control animals after coronary ligation. Four
weeks after injection, all surviving animals underwent blinded
in vivo functional assessment with transthoracic echocardiog-
raphy. On the following day, the animals were killed, and the
heart specimens were processed for immunohistochemical
studies.
Additionally, in group III (n  20), the rats had differenti-
ated mature adult cells (3  106 labeled female C57Bl/6 mouse
skin fibroblasts) injected directly into the myocardium. In group
IIIA (n  10), rats received mouse fibroblast implantation into
the peri-ischemic region after coronary artery ligation, as in
groups I and II, whereas in group IIIB (n  10), similar
fibroblast implantation was carried out without coronary liga-
tion. These animals served as immunologic controls with and
without associated myocardial ischemic injury. They were
killed serially during a 4-week period, and the hearts were
examined for the presence of cellular infiltration and surviving
labeled fibroblasts. Finally, in group IV (n  5), the animals
underwent a sham operation, thoracotomy without coronary
ligation or myocardial injection, with subsequent transthoracic
echocardiography at 4 weeks.
The Journal of ThoracicMSC Isolation and Labeling
Bone marrow cells were harvested from female C57Bl/6 mice
by flushing the femurs and tibias with Dulbecco Modified Eagle
Medium supplemented with 10% fetal bovine serum and 50-
U/mL penicillin-streptomycin according to the method de-
scribed by Wakitani and associates.4 Whole marrow was plated
in tissue culture dishes, and 5 to 7 days later nonadherent
hematopoietic cells were discarded and adherent bone MSCs
were cultured at 37°C with 5% carbon dioxide. The lacZ
reporter gene was transfected into MSCs with pMFG-lacZ
retrovirus-mediated gene transfection, as described previous-
ly.11 The resulting MSCs expressing lacZ were expanded for 4
weeks before transplantation.
To confirm that the MSCs had been properly labeled, these
cells were stained with 5-bromo-4-chloro-3-indoyl--D-galac-
toside (Xgal) for detection of -galactosidase activity. Cells
plated in a 35-mm dish were fixed in 1% glutaraldehyde for 5
minutes at room temperature and subsequently were washed
with phosphate-buffered saline solution. Staining solution at pH
of 7.8 to 8.0,10 which contained 1-mg/mL Xgal, 1-mmol/L
ethyleneglycol-bis(-aminoethyl-ether)-N,N’-tetraacetic acid,
5-mmol/L K3Fe(CN)6, 5-mmol/L K4Fe(CN)6O · 3 H2 O,
2-mmol/L magnesium chloride, and 0.01% sodium deoxy-
cholate,11 was added. The cells were then incubated at 37°C and
protected from light for 16 hours.
Ligation of the Left Coronary Artery and
Transplantation of MSCs
Male Lewis rats (250-300 g) were used in this study as recipient
animals. The animals were anesthetized with isoflurane (MTC
Pharmaceuticals, Cambridge, Ontario, Canada), intubated, and
mechanically ventilated at 80 breaths/min. A left anterolateral
thoracotomy was performed under sterile conditions, and the
left coronary was ligated approximately 1 to 2 mm from its
origin with a 6-0 Prolene suture (Ethicon, Inc, Somerville, NJ).
The ischemic myocardial segment rapidly became pale and
hypocontractile. Mouse MSCs (3  106 cells suspended in 150
L Dulbecco Modified Eagle Medium) were injected directly
into the peri-ischemic region of the myocardium with a 28-
gauge insulin syringe 15 minutes after ligation of the left
coronary artery for animals in the study group. An equal volume
of culture medium was injected into the control animals. He-
mostasis was achieved with a 7-0 Prolene purse-string suture
around the puncture site.
Echocardiography
Transthoracic echocardiography was performed on all animals
at 4 weeks after coronary ligation and cell implantation. The
echocardiographer was blinded to the experimental groups, and
echocardiograms were obtained with a commercially available
echocardiography system (SONO 5500, Hewlett-Packard)
equipped with a 7.5-MHz transducer (Hewlett-Packard Com-
pany, Palo Alto, Calif).12 With isoflurane anesthesia as men-
tioned previously, the heart was first imaged in the 2-dimen-
sional parasternal long-axis view of the LV. Measurements of
maximal LV long-axis lengths (L) and endocardial area tracings
(a) with the leading edge method13 were performed from digital
images captured on cineloops. LV end-diastolic volume
and Cardiovascular Surgery ● Volume 130, Number 4 1115
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lated by the single-plane area-length method14 as 8  a 2 /(3 
3.14  L). LV ejection fraction (LVEF) was then inferred as
(LVEDV  LVESV)/LVEDV. M-mode images were obtained
at the level of papillary muscles of the mitral valves. End-
diastolic and end-systolic diameters of the LV (LVEDd and
LVEDs) were determined. LV fractional shortening (LVFS)
was inferred as (LVEDd  LVEDs)/LVEDd.
Tissue Processing and Staining for -galactosidase
Activity
Animals were killed 1 day after the final echocardiogram (4
weeks after transplantation). The hearts were collected and
rinsed with phosphate-buffered saline solution and perfusion
fixed in 2% paraformaldehyde in phosphate-buffered saline
solution. Staining for -galactosidase activity was performed as
described previously, but with the addition of 0.02% of Nonidet
P-40 (Sigma Laboratories, St Louis, Mo) and 0.01% deoxy-
cholate to the staining solution.10 After Xgal staining, the hearts
were sectioned on the short axis and embedded in paraffin.
Histologic and Immunohistochemical Examination
Heart sections 5 m in thickness were processed for hematox-
ylin and eosin staining, picrosirius red staining, and immuno-
histochemical staining. Immunohistochemical staining was
done for anti––smooth muscle actin (Sigma Laboratories),
troponin IC (Santa-Cruz Biotechnology Inc, Santa Cruz, Calif),
sarcomeric myosin heavy chain molecules with MF 20 (Devel-
opmental Studies Hybridoma Bank, developed under the aus-
pices of the National Institute for Child Health and Develop-
ment and maintained by the University of Iowa, Department of
Biological Sciences, Iowa City, Iowa). Briefly, after deparaf-
finization, sections were placed in boiled citrate buffer (pH 6.0).
After blocking in normal serum, sections were treated with the
respective monoclonal antibodies overnight and with secondary
antibodies the next day. Diaminobenzidine was then used as a
chromogen for light microscopy. Counterstaining of sections
with hematoxylin and eosin was also performed. Cells derived
from the implanted MSCs were identified by their blue nuclei
(-galactosidase labeled) under Olympus light microscopy
(BX-FLA; Olympus, Tokyo, Japan).
Morphometric Analysis
Paraffinized cross-sections of the LV at the level of the papil-
lary muscles were stained with picrosirius red, and morphomet-
ric analysis was performed with a computerized surface deter-
mination method (Image Pro Analyzer; Media Cybernetics, Inc,
Silver Spring, Md) to determine infarct size and thickness. Five
histologic sections were obtained from each heart, and the data
obtained were averaged. Calculations were based upon formu-
las validated in a rat infarct model described by Sandmann and
coworkers.13
Statistical Analysis
All data are reported as mean SD. Comparisons between groups
were conducted with the Student unpaired t test.
1116 The Journal of Thoracic and Cardiovascular Surgery ● OctResults
MSC Culture
MSCs proliferated in the culture medium, adhered to the
bottom of the culture dish, and developed spindle-shaped
morphology. After 3 to 4 passages, the initial 250 to 500
cells that had adhered to the culture dish expanded to
more than 25 million cells. MSCs were transfected with
replication-defective retrovirus carrying the lacZ reporter
gene to trace their fate after transplantation. In vitro
-galactosidase staining demonstrated that transfection
efficiency was nearly 100%.
Mortality
Early mortality was the highest (29.4%, 10/34) in groups
I and II, which had undergone left coronary artery liga-
tion, with 4 of the remaining 24 animals dying in the late
postoperative period before the completion echocardiog-
raphy could be performed. Thus groups I and II had
sample sizes of 10 each for complete follow-up data.
Mortalities in the immunologic control groups IIIA and
IIIB, which had undergone fibroblast transplants with and
without coronary ligation, were 10% (1/10) in each.
There were no deaths (0/5) in group IV, which had
undergone sham surgery. The differences in mortality
among these groups were, however, statistically not
significant.
Histologic and Immunochemical Assessment of
Engrafted Cells
Gross examination of all hearts in the study group (group
I) revealed selective, localized blue discoloration of the
Xgal stain near areas of infarcted myocardium, suggest-
ing the presence of labeled cells (Figure 1, A ). This was
in contrast to the gross specimens of the control group
(group II), which did not demonstrate any blue areas on
gross examination.
Histologic examination of serial LV cross-sections
confirmed that the blue discoloration of the myocardium
visualized in the gross specimens was indeed due to the
presence of  -galactosidase–positive cells (Figure 1, B,
C, and D ). MSCs were scattered throughout the LV
myocardium and were found in all layers; however, cells
were noted to cluster in the subendocardial regions of the
peri-infarct zone. Some cells in this area acquired a
phenotypic appearance similar to that of host cardiomy-
ocytes (Figure 1, C and D ). Many of the surviving cells
stained positively for the cardiomyocyte-specific protein
troponin IC (Figure 1, E ). Few  -galactosidase–positive
cells were found in the fibrous scar; however, those that
were present in the scar tissue had a fibroblastlike
appearance.
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Immunologic Control Groups (Groups IIIA and IIIB)
Animals in this group were subjected to direct intramyo-
cardial injection of an identically labeled mature adult
cell line (mouse skin fibroblasts), with or without coro-
nary artery ligation, and were killed serially (0, 1, 2, 4,
and 7 days) in a 1-week period. Histologic examination
of LV cross-sections showed extensive cellular infiltra-
tion within 1 day, particularly in group IIIA animals with
myocardial ischemic injury from coronary ligation, with
rapid loss of labeled implanted cells. We failed to detect
surviving fibroblasts beyond 4 days in both subgroups
IIIA (Figure 1, F ) and IIIB.
The Journal of ThoracicIn Vivo Assessment of Cardiac Function
LVEF and LVFS were used as indices of LV perfor-
mance. Both parameters were clearly abnormal in both
study (group I) and control (group II) groups; however,
both were significantly better in animals that underwent
MSC implantation at the time of left coronary artery
ligation (LVEF 34.0%  10.7% vs 19.9%  10.0%, P 
.007, and LVFS 24.2%  11.5% vs 14.3%  5.51%, P 
.02; Figure 2). Stroke volume was significantly better in
the study group (0.18  0.05 mL vs 0.12  0.05 mL, P
 .03). End-diastolic volume was significantly lower in
Figure 1. Gross heart specimen
and phenotypic changes of MSCs.
Hearts were harvested at 4 weeks
after cell injection (MSC group, I)
or culture medium injection (con-
trol group, II). Hearts were then
stained for b-gal activity. Intense
blue discoloration was seen on
infarct and peri-infarct areas of
heart in MSC group (A). Hematox-
ylin and eosin staining is shown
at low power (B, 40) and eosin-
only staining is shown at high
power (C, 200, and D, 400) of
the peri-infarct zones of myocar-
dium. Note -galactosidase–pos-
itive cells (arrows) in peri-in-
farcted myocardium (C and D) are
more elongated and phenotypi-
cally resemble surrounding host
cardiomyocytes. Immunostaining
was done for cardiomyocyte-spe-
cific contractile protein troponin
IC (arrow in E, 400). In group III,
histologic examination of LV
cross-sections after injection of
lacZ labeled mouse skin fibro-
blasts (arrow) showed extensive
cellular infiltration within 1 day,
particularly in subgroup IIIA with
associated myocardial ischemic
injury. However, in both sub-
groups with (IIIA) and without
(IIIB) coronary ligations, only few
remaining surviving labeled xe-
nogeneic fibroblasts were found
on day 4 after implantation (F, he-
matoxylin and eosin, 40).the MSC group, with a strong tendency toward lower
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functional parameters were within normal values in the
sham-operated group IV animals (LVEF 53.3%  1.6%,
LVFS 31.9%  4.1%, LVESV 0.17  0.02 mL, LVEDV
0.30  0.03 mL).
Because groups IIIA and IIIB served as immunologic
controls, they were only followed up until all implanted
fibroblasts had been eliminated, which happened within a
week. Thus echocardiographic studies corresponding to
those for groups I and II, which were carried out at 4
weeks postimplantation, were not obtained.
Morphometric Analysis
Data from the LV morphometric analysis demonstrated
that infarct size (expressed as a percentage of LV cir-
cumference) tended to be smaller in the MSC group
(32.1%  13.2% vs 36.6%  7.8%, P  .37). The
infarcted portion of the LV also tended to be thicker in
animals that received intramyocardial MSC injection at
the time of left coronary artery ligation (1.1  0.4 mm vs.
0.9  0.3 mm, P  .17), although the difference did not
reach statistical significance.
Discussion
The ability of xenotransplanted MSCs to survive the host
immune reaction without the use of immunosuppression, par-
ticularly in the midst of the acute inflammatory microenviron-
ment associated with a myocardial infarction, is intriguing.
There is mounting evidence that MSCs are immune-privileged
cells. Liechty and colleagues9 have reported that intraperito-
neally transplanted human MSCs could engraft in fetal sheep,
even after development of immunocompetence. These cells
1118 The Journal of Thoracic and Cardiovascular Surgery ● Octdifferentiated and integrated into host tissues, surviving as long
as 13 months without immunosuppression. Caparrelli and as-
sociates14 and Makkar and coworkers15 reported successful
allogeneic MSC transplantation without the need for immuno-
suppressive medication in a swine model of myocardial infarc-
tion. These cells were shown to survive, differentiate, and
contribute to functional improvement of the host myocardium.
Additionally, our group observed that labeled mouse MSCs
intravenously transplanted into the bone marrow of rats were
later able to be recruited and engraft in damaged rat myocar-
dium, forming a xenotransplant cardiac chimera.10
The presence of immunologic control groups (groups
IIIA and IIIB) in this study strengthens the hypothesis
that MSCs are uniquely immune-privileged cells.
After the intramyocardial injection in rats of labeled
mature differentiated cells (skin fibroblasts) obtained from
the same strain of donor mouse, rapid and massive inflam-
matory cellular infiltration was observed at the sites of
implantation (Figure 2, F), with no surviving cells seen
beyond 4 days. This suggests that, unlike the MSCs, the
implanted mature cells were quickly and completely re-
jected by the xenogeneic recipients, as would be expected.
We studied two immunologic control subgroups (groups
IIIA and IIIB) to examine the possible effects of concomi-
tant myocardial ischemic injury to the fate of these cells. We
found that although myocardial injury induced more vigor-
ous early inflammatory cellular responses, xenogeneic fi-
broblasts were eliminated within several days in both sub-
groups of recipients, in marked contrast to xenogeneic
Figure 2. Indices of LV performance.
Echocardiographic data 4 weeks
after MSC (group I, black bars) or
culture medium (group II, white
bars) injection. Asterisk indicates P
 .007 for group I vs II; double as-
terisk indicates P  .029 for group I
vs II.MSCs.
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to complement this study, our finding of MSC immune privi-
lege is in fact consistent with observations made in many
recent in vitro and in vivo studies. For example, it had been
shown that MSCs cocultured with allogeneic dendric cells or
peripheral lymphocytes suppress the proliferation of CD4 and
CD8 cells. The signaling molecules for such suppression ap-
pear to include transforming growth factor 1 and hepatocyte
growth factor.8 MSCs may even induce suppressive cells from
an already activated allogeneic T cell population.16 In vivo, the
injection of allogeneic MSCs in baboons is tolerated without
immunosuppression,17 and the induction of tolerance by MSCs
has been reported to prolong skin graft survival as well.18 As
mentioned previously, such MSC immune tolerance has also
been reported in a human-to-sheep xenotransplant model.9 Our
findings described here confirm these observations and further
demonstrate that such xenogeneic donor cells can survive the
inflammatory response associated with acute myocardial in-
farction, then differentiate and ameliorate ventricular dysfunc-
tion caused by the coronary occlusion.
Another finding of interest in this study is the in vivo
differentiation of mouse MSCs inside the rat myocardium.
There is strong evidence that MSCs receive signals from the
microenvironment for their differentiation, known as milieu-
dependent differentiation. The results obtained in this study
indicate that such signals are not species specific. Our finding
is consistent with those of Fukuhara and colleagues,19 in which
in vitro coculture of mouse MSCs with neonatal rat cardiomy-
ocytes successfully induced the former to undergo cardiomyo-
cytic differentiation.
Although this is the first study to examine the functional
contribution of transplanted xenogeneic MSCs, it is of interest
The Journal of Thoracicto note that Min and coworkers20 reported improved cardiac
function after implantation of cardiomyocytic progenitor cells
derived from xenogeneic embryonic stem cells. In our study,
assessment of in vivo cardiac function with transthoracic echo-
cardiography demonstrated that LV function was clearly ab-
normal in both the study and control groups after the extensive
myocardial insult produced by proximal left coronary artery
ligation. However, animals that received MSC injection had
significantly better indices of LV performance than did control
animals. Our data suggest that hearts engrafted with MSCs had
a tendency to dilate less than comparable control hearts, as
demonstrated by the lower LVEDV. Contractile function also
improved in the MSC group, with higher stroke volumes.
Many studies of MSC therapy for infarcted myocardium have
reported improved contractile function,7 although the mecha-
nism of the improvement remains unclear.21 It has been sug-
gested that functional improvement may be attributable to the
improved contractile properties contributed by the neocardio-
myocytes, by attenuation of remodeling and LV dilatation, and
possibly by neoangiogenesis and improved performance of
surviving myocytes. It is likely that the functional improve-
ment is related to some combination of these factors, although
this has yet to be definitively documented.
One of the major limitations in this report is lack of
quantitative data on cell survival and differentiation. This
important issue is under intensive study by us and others.
In a mechanistic study, it is also desirable to identify
more rigorously the cell population that exhibits such
immune tolerance characteristics. Cell sorting is usually
carried out by identifying and separating cell populations
by their unique surface markers. Unfortunately, so far
Figure 3. Components of stroke vol-
ume. Echocardiogram data performed
at 4 weeks after MSC (group I, dia-
monds) or culture medium (group II,
squares) injection comparing LVEDV
and LVESV. Asterisk indicates P 
.009 for group I vs II.there has been no unanimous consensus on cell markers
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potent stem cells. For example, it has been thought that
hematopoietic stem cells are CD34, whereas marrow
stromal stem cells are CD34. However, Sato and asso-
ciates22 showed recently that hematopoietic stem cells
are originally derived from CD34 fraction, and CD34
expression marks stem cell activation and mobilization.
Nevertheless, our observation reported here does indicate
that MSCs contain a population or populations of
uniquely immunotolerant stem cells. It should be noted
also that in many previous experimental and clinical
studies such mixed population MSCs have been used
without evidence of any harmful effects to the recipients.
In this study, we did not carry out karyotype analysis
to address the possibility of a cell fusion phenomenon,23
which is a highly controversial issue at present, although
transdifferentiation of adult stem cells has also been
confirmed.24 If the labeled cardiomyocytes are the result
of labeled MSC transdifferentiation, they should have
euploid nuclei, but if they are the result of spontaneous
cell fusion between a host cardiomyocyte and MSC, as
some have suggested, they should be polyploid hybrid
cells. Conflicting reports have been published for the
frequency of cell fusion, which may ultimately depend on
the type of stem cells and the experimental conditions
used in these studies. Nevertheless, if the cell fusion is
the predominant phenomenon, how such fused cells
might contribute to improved ventricular function would
be a perplexing question.
We believe that if our findings reported here can be
further confirmed in other animal species, and with even
longer follow-up to examine the possibility of chronic
rejections, there could be profound clinical implications
because of the possibility of using MSCs as “universal
donor cells,” which would require no immunosuppressive
therapy for tissue regeneration.25 To observe immune
tolerance, we chose a xenotransplant model for our ex-
periments because it is immunologically more challeng-
ing than a model with allogeneic cells. It is important to
emphasize that clinically, even if immunologically fea-
sible, we would still favor the use of allotransplant cells
as universal donor cells rather than using xenogeneic
cells because of other risks associated with the latter in
general, such as cross-species transmission of retroviral
infections. However, the logistic advantages of using
allogeneic universal donor cells rather than autologous
cells, the feasibility of using donor cells from genetically
normal individuals for recipients with genetic defects,
and the potential use of young donor MSCs for senescent
recipients whose autologous MSCs may be functionally
compromised are all fascinating possibilities worthy of
further exploration.
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